Nektar Therapeutics (NASDAQ: NKTR) kicked off on Monday, up 9.92% from the previous trading day, before settling in for the closing price of $0.72. Over the past 52 weeks, NKTR has traded in a range of $0.43-$1.52.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -3.00%. While this was happening, its average annual earnings per share was recorded -38.74%. With a float of $179.42 million, this company’s outstanding shares have now reached $186.10 million.
Let’s determine the extent of company efficiency that accounts for 61 employees. In terms of profitability, gross margin is 74.61%, operating margin of -131.01%, and the pretax margin is -147.55%.
Nektar Therapeutics (NKTR) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Nektar Therapeutics is 3.59%, while institutional ownership is 64.60%. The most recent insider transaction that took place on May 19 ’25, was worth 7,177. In this transaction Chief R&D Officer of this company sold 10,712 shares at a rate of $0.67, taking the stock ownership to the 305,892 shares. Before that another transaction happened on May 19 ’25, when Company’s Chief Legal Officer sold 9,996 for $0.67, making the entire transaction worth $6,697. This insider now owns 314,296 shares in total.
Nektar Therapeutics (NKTR) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -38.74% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -16.46% during the next five years compared to 25.49% growth over the previous five years of trading.
Nektar Therapeutics (NASDAQ: NKTR) Trading Performance Indicators
Take a look at Nektar Therapeutics’s (NKTR) current performance indicators. Last quarter, stock had a quick ratio of 3.24. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.70.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.64, a number that is poised to hit -0.20 in the next quarter and is forecasted to reach -0.80 in one year’s time.
Technical Analysis of Nektar Therapeutics (NKTR)
Looking closely at Nektar Therapeutics (NASDAQ: NKTR), its last 5-days average volume was 1.84 million, which is a drop from its year-to-date volume of 2.18 million. As of the previous 9 days, the stock’s Stochastic %D was 90.08%. Additionally, its Average True Range was 0.07.
During the past 100 days, Nektar Therapeutics’s (NKTR) raw stochastic average was set at 44.68%, which indicates a significant decrease from 88.85% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 67.76% in the past 14 days, which was lower than the 95.83% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.6801, while its 200-day Moving Average is $0.9846. However, in the short run, Nektar Therapeutics’s stock first resistance to watch stands at $0.8440. Second resistance stands at $0.8917. The third major resistance level sits at $0.9635. If the price goes on to break the first support level at $0.7245, it is likely to go to the next support level at $0.6527. Should the price break the second support level, the third support level stands at $0.6050.
Nektar Therapeutics (NASDAQ: NKTR) Key Stats
The company with the Market Capitalisation of 148.21 million has total of 186,104K Shares Outstanding. Its annual sales at the moment are 98,430 K in contrast with the sum of -118,960 K annual income. Company’s last quarter sales were recorded 10,460 K and last quarter income was -50,880 K.
